Literature DB >> 15051887

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.

Zhihai Si1, Navid Madani, Jason M Cox, Jason J Chruma, Jeffrey C Klein, Arne Schön, Ngoc Phan, Liping Wang, Alyssa C Biorn, Simon Cocklin, Irwin Chaiken, Ernesto Freire, Amos B Smith, Joseph G Sodroski.   

Abstract

When interacting with the CD4 receptor, the HIV gp120 envelope glycoprotein undergoes conformational changes that allow binding to the chemokine receptor. Receptor binding is proposed to lead to conformational changes in the gp41 transmembrane envelope glycoprotein involving the creation and/or exposure of a coiled coil consisting of three heptad repeat (HR) sequences. The subsequent interaction of the HR2 region of gp41 with this coiled coil results in the assembly of a six-helix bundle that promotes the fusion of the viral and target cell membranes. Here we show that CD4 binding to gp120 induces the formation and/or exposure of the gp41 HR1 coiled coil in a process that does not involve gp120 shedding and that depends on the proteolytic maturation of the gp160 envelope glycoprotein precursor. Importantly, BMS-806 and related HIV-1 entry inhibitors bind gp120 and block the CD4 induction of HR1 exposure without significantly affecting CD4 binding. Moreover, these compounds do not disrupt gp120-chemokine receptor binding or the HR1-HR2 interaction within gp41. These studies thus define a receptor-induced conformational rearrangement of gp120-gp41 that is important for both CD4-dependent and CD4-independent HIV-1 entry and is susceptible to inhibition by low-molecular-weight compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051887      PMCID: PMC387369          DOI: 10.1073/pnas.0307953101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

2.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

4.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

5.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

6.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

7.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

8.  Capture of an early fusion-active conformation of HIV-1 gp41.

Authors:  R A Furuta; C T Wild; Y Weng; C D Weiss
Journal:  Nat Struct Biol       Date:  1998-04

9.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

10.  CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Authors:  N Sullivan; Y Sun; Q Sattentau; M Thali; D Wu; G Denisova; J Gershoni; J Robinson; J Moore; J Sodroski
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

View more
  137 in total

1.  Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.

Authors:  Yijun Zhang; James H Chapman; Asim Ulcay; Richard E Sutton
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

3.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 4.  Microbicides: topical prevention against HIV.

Authors:  Robin J Shattock; Zeda Rosenberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

5.  Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid.

Authors:  Sandhya Kortagere; Navid Madani; Marie K Mankowski; Arne Schön; Isaac Zentner; Gokul Swaminathan; Amy Princiotto; Kevin Anthony; Apara Oza; Luz-Jeannette Sierra; Shendra R Passic; Xiaozhao Wang; David M Jones; Eric Stavale; Fred C Krebs; Julio Martín-García; Ernesto Freire; Roger G Ptak; Joseph Sodroski; Simon Cocklin; Amos B Smith
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 6.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

8.  Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.

Authors:  Wen Yuan; Jessica Bazick; Joseph Sodroski
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

9.  Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.

Authors:  Arne Schön; Navid Madani; Jeffrey C Klein; Amy Hubicki; Danny Ng; Xinzhen Yang; Amos B Smith; Joseph Sodroski; Ernesto Freire
Journal:  Biochemistry       Date:  2006-09-12       Impact factor: 3.162

10.  Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120.

Authors:  Hyun-Su Lee; Mark Contarino; M Umashankara; Arne Schön; Ernesto Freire; Amos B Smith; Irwin M Chaiken; Lynn S Penn
Journal:  Anal Bioanal Chem       Date:  2009-12-17       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.